SCHEMBL22967643

SCHEMBL22967643

CCC(C)Nc1ccc(OCc2cccc(F)c2)c(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 5/20 0.48
GAK O14976 1/20 0.48
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
LMNA P02545 3/20 0.48
PABPC1 P11940 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MAOB P27338 1/20 0.46
CTSV O60911 3/20 0.46
CTSL P07711 3/20 0.46
CSF1R P07333 2/20 0.45
KIT P10721 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
KDM4E B2RXH2 1/20 0.44
PLA2G1B P04054 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22967587 0.89 EGFR (0.51) EGFRGAKALDH1A1MEN1KMT2A
SCHEMBL22967590 0.83 EGFR (0.52) EGFRGAKALDH1A1MEN1KMT2A
SCHEMBL21340751 0.83 EGFR (0.53) EGFRGAKALDH1A1MEN1KMT2A
SCHEMBL17210836 0.77 MAOB (0.55) EGFRGAKALDH1A1MEN1KMT2A
SCHEMBL6961120 0.77 LMNA (0.47) EGFRGAKALDH1A1LMNAMAOB
SCHEMBL12864874 0.76 MAOB (0.56) EGFRGAKALDH1A1MEN1KMT2A
SCHEMBL6962368 0.76 MRGPRX4 (0.51) EGFRGAKALDH1A1LMNAMAOB
SCHEMBL4333127 0.75 TSHR (0.51) EGFRALDH1A1SMN1; SMN2CTSVCTSL
SCHEMBL1406548 0.75 MAOB (0.60) EGFRGAKALDH1A1MEN1KMT2A
SCHEMBL6961577 0.75 EGFR (0.61) EGFRGAKERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-10 US disclosed
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF ACCSALUS BIOSCIENCES LIMITED (VG) 2021-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof WNK1, WNK2, WNK3 EGFR 3163/4885GAK 174/4885ALDH1A1 1467/4885
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF WNK1, WNK2, WNK3 EGFR 3163/4885GAK 174/4885ALDH1A1 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.